Nivolumab-Induced Granuloma Annulare.

Immune-checkpoint inhibitors (ICIs) such as pembrolizumab and nivolumab have transformed oncologic therapeutic modalities. By disrupting tumor-induced immunosuppression, ICIs have facilitated effective treatment of numerous malignancies, including metastatic melanoma; however, due to the ensuing disturbance of the immune system, various immune-mediated adverse reactions have been reported with ICI therapy. We present a case of nivolumab-induced granuloma annulare in a 54-year-old woman. Recognition of the association between ICI therapy and cutaneous adverse reactions is crucial to ensure accurate diagnosis and adequate treatment of such reactions in patients taking ICIs.